Natera, Inc. $NTRA Shares Sold by Granahan Investment Management LLC

Key Points

• Granahan Investment Management LLC has reduced its holdings in Natera, Inc. by 47.3%, selling over 26,000 shares and now holding 29,234 shares valued at approximately $4.1 million.
• Natera reported a quarterly earnings loss of ($0.74) per share, missing estimates, but saw revenue increase by 32.2% year-over-year, totaling $546.6 million.
• Despite recent insider selling, several analysts reaffirmed positive ratings for Natera, with price targets ranging from $195.00 to $268.00 on the stock.

Granahan Investment Management LLC cut its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 47.3% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 29,234 shares of the medical research company's stock after selling 26,208 shares during the period. Granahan Investment Management LLC's holdings in Natera were worth $4,134,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of NTRA. BNP Paribas Financial Markets lifted its position in Natera by 1,126.1% during the 4th quarter. BNP Paribas Financial Markets now owns 233,890 shares of the medical research company's stock worth $37,025,000 after acquiring an additional 214,814 shares in the last quarter. Captrust Financial Advisors lifted its position in Natera by 36.0% during the 4th quarter. Captrust Financial Advisors now owns 7,737 shares of the medical research company's stock worth $1,225,000 after acquiring an additional 2,048 shares in the last quarter. Centiva Capital LP acquired a new position in Natera during the 4th quarter worth approximately $418,000. Colonial Trust Co SC lifted its position in Natera by 7.8% during the 4th quarter. Colonial Trust Co SC now owns 1,325 shares of the medical research company's stock worth $210,000 after acquiring an additional 96 shares in the last quarter. Finally, EP Wealth Advisors LLC acquired a new position in Natera during the 4th quarter worth approximately $242,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Natera

In other news, Director Gail Boxer Marcus sold 2,496 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $133.17, for a total value of $332,392.32. Following the completion of the transaction, the director owned 5,763 shares of the company's stock, valued at approximately $767,458.71. This represents a 30.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $166.62, for a total value of $499,860.00. Following the completion of the transaction, the insider directly owned 120,859 shares of the company's stock, valued at approximately $20,137,526.58. The trade was a 2.42% decrease in their position. The disclosure for this sale can be found here. Insiders sold 60,423 shares of company stock valued at $9,117,416 over the last three months. 5.63% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Stephens reaffirmed an "overweight" rating and issued a $183.00 target price on shares of Natera in a research report on Friday, August 15th. Wall Street Zen lowered Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Morgan Stanley reaffirmed an "overweight" rating and issued a $195.00 target price on shares of Natera in a research report on Sunday, August 10th. Royal Bank Of Canada set a $268.00 price target on Natera and gave the company an "outperform" rating in a research report on Tuesday, September 2nd. Finally, Cowen reissued a "buy" rating on shares of Natera in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating and seventeen have assigned a Buy rating to the stock. According to MarketBeat, Natera currently has a consensus rating of "Buy" and an average price target of $194.00.

Natera Price Performance

Shares of NTRA stock traded down $0.63 on Monday, hitting $167.39. 841,017 shares of the stock traded hands, compared to its average volume of 1,058,112. The company has a market capitalization of $22.97 billion, a PE ratio of -87.64 and a beta of 1.68. The company's fifty day moving average is $154.32 and its 200 day moving average is $153.72. Natera, Inc. has a 1-year low of $114.62 and a 1-year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. During the same period in the prior year, the business earned ($0.30) earnings per share. Natera's quarterly revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.